论文部分内容阅读
目的:观察软肝抗纤汤联合恩替卡韦分散片对肝硬化肝纤维化的影响。方法:收集80例肝硬化肝纤维化湿浊气阻兼血瘀证患者作为研究对象,随机分为联合组及西药组各40例,2组均以恩替卡韦分散片治疗,联合组加用软肝抗纤汤治疗,观察治疗前后2组患者的肝硬度、肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBil)、谷草转氨酶(AST)]与肝纤维化指标[透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)]的变化,采用世界卫生组织生存质量测定量表简表(WHOQOL-BRFE)评定2组患者的生存质量。结果:治疗后,2组肝硬度值、ALT、TBil、AST、HA、LN、PCⅢ、Ⅳ-C均较治疗前降低,联合组各项指标值均低于对照组,差异均有统计学意义(P<0.05)。2组生存质量生理领域、心理领域、社会关系领域、环境领域评分均较治疗前升高,联合组4项评分均高于西药组,差异均有统计学意义(P<0.05)。结论:软肝抗纤汤联合恩替卡韦分散片通过有效改善肝硬化肝纤维化患者的肝功能指标及肝纤维化指标,继而达到减小肝硬度及提高患者生存质量的目的。
Objective: To observe the effects of Ruangang Kangxian Decoction combined with entecavir dispersible tablets on liver cirrhosis with hepatic fibrosis. Methods: Eighty patients with cirrhosis of liver fibrosis with damaging qi stagnation and blood stasis syndrome were randomly divided into 40 cases in combination group and western medicine group. The two groups were treated with entecavir dispersible tablets. The combined group was treated with soft liver Anti-fibangolic solution was used to observe the changes of liver cirrhosis, liver function index (ALT, TBil, AST) and liver fibrosis index [hyaluronidase (HA), laminin (LN), type Ⅲ procollagen (PCⅢ), type Ⅳ collagen (Ⅳ-C)] were measured. The WHOQOL-BRFE The patient’s quality of life. Results: After treatment, the values of liver cirrhosis, ALT, TBil, AST, HA, LN, PCⅢ, Ⅳ-C in both groups were lower than those before treatment, and the indexes in the combined group were lower than those in the control group (P <0.05). The scores of quality of life in the two groups were higher in the physiological, psychological, social and environmental fields than those in the western medicine group (all P <0.05). Conclusion: Rugan Kangxian Decoction combined with entecavir dispersible tablets can effectively reduce hepatic fibrosis and hepatic fibrosis in cirrhotic patients with liver fibrosis, and then achieve the goal of reducing liver stiffness and improving patients’ quality of life.